-       Report 
   - November 2025
    -  274 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - June 2025
    -  290 Pages 
    Global
   
   From       €4482EUR$4,995USD£3,934GBP 
                -       Report 
   - July 2025
     Global
   
   From       €4397EUR$4,900USD£3,859GBP 
                -       Report 
   - June 2025
    -  110 Pages 
    Global
   
   From       €5339EUR$5,950USD£4,686GBP 
                  -       Report 
   - August 2025
    -  149 Pages 
    Global
   
   From       €2287EUR$2,549USD£2,008GBP 
      €2691EUR$2,999USD£2,362GBP 
                   -       Report 
   - October 2025
    -  188 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  194 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                -       Report 
   - October 2025
    -  250 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - March 2025
    -  200 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - February 2025
    -  200 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                  -       Report 
   - October 2025
    -  180 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - October 2025
    -  194 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  199 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  192 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  185 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  192 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                -       Report 
   - November 2025
    -  374 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  441 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  173 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
             
         Rheumatoid Arthritis (RA) is a chronic autoimmune disorder that affects the joints and other organs. It is a type of inflammatory arthritis that is caused by an overactive immune system. RA is a major cause of disability and is the most common form of inflammatory arthritis. It affects people of all ages, but is more common in women than men. Symptoms of RA include joint pain, swelling, stiffness, and decreased range of motion. Treatment for RA includes medications, physical therapy, and lifestyle    changes.
The RA market within the context of Allergy and Immunology is a rapidly growing market. It is driven by the increasing prevalence of RA, the development of new treatments, and the increasing demand for better treatments. The market is expected to grow due to the increasing awareness of RA and the increasing demand for better treatments.
Some companies in the RA market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer, and Roche. Show Less   Read more